Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma

被引:11
作者
Wang, Hu [1 ]
Yang, Zhan [1 ]
He, Xingyu [1 ]
Guo, Fengran [1 ]
Sun, Hao [1 ]
Xu, Sen [1 ]
Xu, Chao [1 ]
Wang, Zhu [1 ]
Wen, Hongzhuang [1 ]
Teng, Zhihai [1 ]
Wang, Yaxuan [1 ]
Han, Zhenwei [1 ]
机构
[1] Hebei Med Univ, Hosp 2, Dept Urol, 215 West Heping Rd, Shijiazhuang 050000, Peoples R China
关键词
Cuproptosis; PDHB; Clear cell renal cell carcinoma; Tumor immune microenvironment; INTERFERON-ALPHA; COPPER; SURVIVAL; EVEROLIMUS; SELENIUM; DEATH; IRON; ZINC;
D O I
10.1186/s12885-023-11324-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Cuproptosis is a newly discovered programmed cell death dependent on mitochondrial respiratory disorder induced by copper overload. Pyruvate dehydrogenase E1 subunit beta (PDHB) is one of the cuproptosis genesand is a nuclear-encoded pyruvate dehydrogenase, which catalyzes the conversion of pyruvate to acetyl coenzyme A. However, the mechanism of PDHB in clear cell renal cell carcinoma (ccRCC) remains unclear.Methods We used data from TCGA and GEO to assess the expression of PDHB in normal and tumor tissues. We further analyzed the relationship between PDHB and somatic mutations and immune infiltration. Finally, we preliminarily explored the impact of PDHB on ccRCC.Results The expression level of PDHB was lower in tumor tissue compared with normal tissue. Meanwhile, the expression level of PDHB was also lower in high-grade tumors than low-grade tumors. PDHB is positively correlated with prognosis in ccRCC. Furthermore, PDHB may be associated with decreased risk of VHL, PBRM1 and KDM5C mutations. In 786-O cells, copper chloride could promote the expression of cuproptosis genes (DLAT, PDHB and FDX1) and inhibit cell growth. Last but not least, we found that PDHB could inhibit the proliferation and migration of ccRCC cells.Conclusion Our results demonstrated that PDHB could inhibit the proliferation, migration and invasion in ccRCC cells, which might be a prognostic predictor of ccRCC. Targeting this molecular might provide a new therapeutic strategy for patients with advanced ccRCC.
引用
收藏
页数:13
相关论文
共 54 条
[31]   Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma [J].
Peng, Xingyu ;
Zhu, Jinfeng ;
Liu, Sicheng ;
Luo, Chen ;
Wu, Xun ;
Liu, Zitao ;
Li, Yanzhen ;
Yuan, Rongfa .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[32]   Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore [J].
Pruis, Sil-ling ;
Aziz, Mohamed Ismail Abdul ;
Pearce, Fiona ;
Tan, Min Han ;
Wu, David Bin-Chia ;
Ng, Kwong .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (02) :126-133
[33]   Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial [J].
Rini, Brian I. ;
Powles, Thomas ;
Atkins, Michael B. ;
Escudier, Bernard ;
McDermott, David F. ;
Suarez, Cristina ;
Bracarda, Sergio ;
Stadler, Walter M. ;
Donskov, Frede ;
Lee, Jae Lyun ;
Hawkins, Robert ;
Ravaud, Alain ;
Alekseev, Boris ;
Staehler, Michael ;
Uemura, Motohide ;
De Giorgi, Ugo ;
Mellado, Begona ;
Porta, Camillo ;
Melichar, Bohuslav ;
Gurney, Howard ;
Bedke, Jens ;
Choueiri, Toni K. ;
Parnis, Francis ;
Khaznadar, Tarik ;
Thobhani, Alpa ;
Li, Shi ;
Piault-Louis, Elisabeth ;
Frantz, Gretchen ;
Huseni, Mahrukh ;
Schiff, Christina ;
Green, Marjorie C. ;
Motzer, Robert J. .
LANCET, 2019, 393 (10189) :2404-2415
[34]   Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 [J].
Rini, Brian I. ;
Halabi, Susan ;
Rosenberg, Jonathan E. ;
Stadler, Walter M. ;
Vaena, Daniel A. ;
Ou, San-San ;
Archer, Laura ;
Atkins, James N. ;
Picus, Joel ;
Czaykowski, Piotr ;
Dutcher, Janice ;
Small, Eric J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5422-5428
[35]   Immune checkpoint inhibitors in renal cell carcinoma [J].
Ross, Kirsty ;
Jones, Rob J. .
CLINICAL SCIENCE, 2017, 131 (21) :2627-2642
[36]   Serum Levels of Selenium, Zinc, Copper, Manganese, and Iron in Prostate Cancer Patients [J].
Saleh, Saleh A. K. ;
Adly, Heba M. ;
Abdelkhaliq, Altaf A. ;
Nassir, Anmar M. .
CURRENT UROLOGY, 2020, 14 (01) :44-49
[37]   Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach [J].
Shinder, Brian M. ;
Rhee, Kevin ;
Farrell, Douglas ;
Farber, Nicholas J. ;
Stein, Mark N. ;
Jang, Thomas L. ;
Singer, Eric A. .
FRONTIERS IN ONCOLOGY, 2017, 7
[38]   Lipoic acid metabolism and mitochondrial redox regulation [J].
Solmonson, Ashley ;
DeBerardinis, Ralph J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (20) :7522-7530
[39]   Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer [J].
Song, Shaoran ;
Zhang, Miao ;
Xie, Peiling ;
Wang, Shuhong ;
Wang, Yaochun .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[40]   Cuproptosis: a copper-triggered modality of mitochondrial cell death [J].
Tang, Daolin ;
Chen, Xin ;
Kroemer, Guido .
CELL RESEARCH, 2022, 32 (05) :417-418